Foon K - Search Results

1

Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia.

McHayleh W, Foon K, Redner R, Sehgal R, Raptis A, Agha M, Luong TM, Schlesselman JJ, Boyiadzis M. McHayleh W, et al. Among authors: foon k. Cancer. 2010 Jun 15;116(12):3001-5. doi: 10.1002/cncr.25078. Cancer. 2010. PMID: 20564405 Free article.

2

Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors.

Szczepanski MJ, Szajnik M, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Szczepanski MJ, et al. Cancer Immunol Immunother. 2010 Jan;59(1):73-9. doi: 10.1007/s00262-009-0724-5. Epub 2009 Jun 13. Cancer Immunol Immunother. 2010. PMID: 19526239 Free PMC article.

3

Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.

Mehta DR, Foon KA, Redner RL, Raptis A, Agha M, Hou JZ, Duggal S, Luong TM, Schlesselman JJ, Boyiadzis M. Mehta DR, et al. Among authors: foon ka. Leuk Res. 2011 Jul;35(7):885-8. doi: 10.1016/j.leukres.2010.12.030. Epub 2011 Feb 18. Leuk Res. 2011. PMID: 21315448

4

Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease.

Boyiadzis M, Foon KA, Pavletic S. Boyiadzis M, et al. Expert Opin Biol Ther. 2007 Dec;7(12):1789-97. doi: 10.1517/14712598.7.12.1789. Expert Opin Biol Ther. 2007. PMID: 18034645 Review.

5

Approved monoclonal antibodies for cancer therapy.

Boyiadzis M, Foon KA. Boyiadzis M, et al. Expert Opin Biol Ther. 2008 Aug;8(8):1151-8. doi: 10.1517/14712598.8.8.1151. Expert Opin Biol Ther. 2008. PMID: 18613766 Review.

6

Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.

Jacobs SA, Swerdlow SH, Kant J, Foon KA, Jankowitz R, Land SR, DeMonaco N, Joyce J, Osborn JL, Evans TL, Schaefer PM, Luong TM. Jacobs SA, et al. Clin Cancer Res. 2008 Nov 1;14(21):7088-94. doi: 10.1158/1078-0432.CCR-08-0529. Clin Cancer Res. 2008. PMID: 18981007 Clinical Trial.

7

Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.

Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, Meisner D, Laman A, Sulecki M, Butchko A, Schaefer P, Lenzer D, Tarhini A. Foon KA, et al. J Clin Oncol. 2009 Feb 1;27(4):498-503. doi: 10.1200/JCO.2008.17.2619. Epub 2008 Dec 15. J Clin Oncol. 2009. PMID: 19075274

8

Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia.

Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Szczepanski MJ, et al. Clin Cancer Res. 2009 May 15;15(10):3325-32. doi: 10.1158/1078-0432.CCR-08-3010. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417016 Free PMC article.

9

Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.

Boyiadzis M, Redner RL, Raptis A, Hou JZ, Agha M, Foon KA. Boyiadzis M, et al. Among authors: foon ka. Ann Hematol. 2011 Jun;90(6):733-5. doi: 10.1007/s00277-010-1076-0. Epub 2010 Sep 21. Ann Hematol. 2011. PMID: 20857113 Clinical Trial. No abstract available.

10

Natural killer cells: from bench to cancer therapy.

Boyiadzis M, Foon KA. Boyiadzis M, et al. Expert Opin Biol Ther. 2006 Oct;6(10):967-70. doi: 10.1517/14712598.6.10.967. Expert Opin Biol Ther. 2006. PMID: 16989578 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

243 results

Search Page